BioMarin Pharmaceutical News

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! SAN RAFAEL, Calif., May 14, 2013 -- BioMarin Pharmaceutical Inc.

The firm currently has a "hold" rating on the stock. Shares of Biomarin Pharm traded up 1.73% during mid-day trading on Monday, hitting $68.85. Biomarin Pharm has a one year low of $33.75 and a one year high of $66.63. The stock's 50-day moving average is currently $62.1. The company's market cap is $9.571 billion.

The firm set a "buy" rating on the stock. A number of other analysts have also recently weighed in on BMRN.

StockCall.com Provides Stock Research on Delcath Systems Inc., Akorn Inc., Astex Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., and Forest Laboratories Inc.

BioMarin Pharmaceutical Inc. recently reported a net loss of $39.8 million, or 31 cents per share, for the first quarter ended March 31, compared to a net loss of $24 million in the same period last year.

's stock had its "neutral" rating reiterated by Zacks in a research note issued to investors on Tuesday, AnalystRatingsNetwork reports.

Recently, shares of Catalyst Pharmaceutical Partners and Vertex Pharmaceuticals spiked dramatically upward, drawing the attention of many traders and investors.

Raptor Pharmaceutical Corp. today said the U.S. Food and Drug Administration approved its drug designed for the treatment of nephropathic cystinosis, a rare and possibly life-threatening metabolic disorder.

Celsus Therapeutics , an emerging growth, development-stage biotech company, announced the addition of Pharma/Biotech industry veteran Fredric Price to the Company's Board of Directors.

The firm currently has an "outperform" rating on the stock. Shares of Biomarin Pharm traded up 0.49% during mid-day trading on Friday, hitting $63.18. Biomarin Pharm has a one year low of $33.75 and a one year high of $66.63. The stock's 50-day moving average is currently $62.1. The company's market cap is $7.967 billion.

Good day, ladies and gentlemen, and thank you for your patience. You've joined the BioMarin Pharmaceutical First Quarter 2013 Financial Results Conference Call.

San Rafael-based BioMarin Pharmaceutical Inc. on Thursday announced a net loss of $39.8 million for the first quarter of 2013 compared with a net loss of $24 million for the first quarter of 2012.

Biomarin Pharm posted its quarterly earnings results on Thursday. The company reported earnings per share for the quarter, missing the analysts' consensus estimate of by $0.01, Stock Ratings Network.com reports.